The S&P 500 closed above 7,800 for the first time ever on Tuesday, but the real action was in single stocks. Constellation Energy jumped 12% after Google confirmed its nuclear deal, Option Care Health soared 33% on a $5.8 billion buyout, and Ciena rode a fresh wave of AI-networking enthusiasm. Below are the stocks to watch tomorrow, Wednesday, October 7, with closing prices, key levels and the catalysts behind each move.
Stocks to Watch Tomorrow: Tuesday’s Market Snapshot
| Metric | Tuesday Close / Reading |
|---|---|
| S&P 500 | 7,818.93 (+0.58%), record close |
| Nasdaq Composite | 27,599.79 (+0.45%), record close |
| Dow Jones Industrial Average | 51,521.28 (+0.49%) |
| Russell 2000 | 2,830.44 (-0.59%) |
| Macro Backdrop | Treasury yields and oil eased from recent highs; Q3 bank earnings start next week |
The S&P 500 and Nasdaq both closed at records as Nvidia and AMD led tech higher, while the Russell 2000 slipped as small caps lagged.
Data note: Closes are Tuesday, October 6 figures where a source published one. Where feeds disagreed or no close was available, we say “near,” “roughly,” or “not confirmed.” Derived figures are labeled. Support and resistance levels are analytical zones, not guaranteed targets.
1. Constellation Energy (CEG) | Last Close $300.40 (+12.25%) | Google Deal Confirmed
From Rumor to Signed: The $4.3 Billion Nuclear Contract That Reclaimed the 200-Day
Google and Constellation announced a 20-year agreement adding 890 MW of nuclear capacity on the PJM grid, confirming Bloomberg’s earlier report. We covered the setup in our overnight note on CEG.
| Metric | Value |
|---|---|
| Last Close | $300.40 (per TECHi; single source) |
| Previous Close | $267.62 (Monday, Oct 5) |
| Day’s Move | +12.25% (+$32.78) |
| Day’s Range | High $309.59 (low not confirmed) |
| 52-Week Range | $228.63 – $412.70 |
| Market Cap | ~$106.4B |
| P/E / Dividend | Roughly 29x trailing (approx.) / $1.71 per year (~0.57% yield) |
| Volume vs. Average | Not confirmed (Monday: 3.52M vs. 2.80M average) |
| YTD | Roughly -15% (derived; was -24% Monday) |
| Analyst View | Buy; average target about $344 pre-deal (range $296–$441) |
| Support 1 / 2 / 3 | $287–$290 / $271 / $267.62 |
| Resistance 1 / 2 / 3 | $309.59 / ~$325 / ~$343–$344 |
Catalyst & Latest News: Constellation will invest more than $4.3 billion to upgrade 11 reactors in Illinois, Pennsylvania and New Jersey, with power arriving as soon as 2028. TIKR notes that a separate agreement covers roughly 2,700 MW from existing PJM assets, so the total deal is about 3.6 GW. Financial terms were not disclosed.
Technicals: The stock cleared its 20-, 50- and 200-day averages (roughly $267, $271 and $287, derived from Finviz) in one session. That makes $287–$290 the key level to hold.
Fundamentals: The company has now signed hyperscaler deals with Microsoft, Amazon and Google. Q2 adjusted earnings beat estimates and guidance was raised.
Bull Case: Contract visibility, a reclaimed 200-day and an oversold start to the year. Bear Case: A 12% gap leaves little margin for error, and the PJM regulatory overhang remains.
What to Watch:
- A hold above $287–$290
- Analyst target raises
- PJM and FERC updates
Forecast: Holding $290 targets the $309.59 high. A close under $287 would put the gap at risk.
Why This Matters: CEG is the clearest read on whether AI power demand becomes signed, long-dated revenue.
2. Option Care Health (OPCH) | Last Close $31.00 (+32.65%) | $32.05 Cash Buyout
A 37% Premium, a $1.05 Spread and 65 Million Shares Changing Hands
CD&R and McKesson agreed to acquire Option Care for $32.05 per share in cash, a deal valued near $5.8 billion including debt.
| Metric | Value |
|---|---|
| Last Close | $31.00 (after-hours $31.05) |
| Previous Close | $23.37 (Monday, Oct 5) |
| Day’s Move | +32.65% (+$7.63) |
| Day’s Range | ~$30.97 – $31.11 |
| 52-Week Range | $18.01 – $36.80 |
| Market Cap | ~$4.5B |
| P/E / Dividend | ~23.5x (EPS $1.32) / None |
| Volume vs. Average | 65.07M vs. ~1.98M (~33x) |
| YTD | About -4% |
| Analyst View | Jefferies downgraded to Hold, target $32.05 |
| Support 1 / 2 / 3 | ~$30.50 / ~$28.89 / $23.37 |
| Resistance 1 / 2 / 3 | ~$31.50 / $32.05 / $36.80 |
Catalyst & Latest News: The deal needs shareholder and regulatory approval and is expected to close in the first half of 2027. CD&R would hold 51% and McKesson 49%.
Technicals: The stock is pinned in a tight band under the offer. Benzinga flags the spread at about $1 per share.
Fundamentals: The shares had fallen sharply earlier in the year after a weak first quarter. Next earnings are listed for November 4.
Bull Case: A competing bid or faster close could narrow the spread. Bear Case: Deal risk, a long timeline, and a downside to the low $20s if it breaks.
What to Watch:
- Spread to $32.05
- Proxy and regulatory filings
- Any competing offer
Forecast: Expect low volatility near $31 and drift toward $32 as the deal progresses.
Why This Matters: OPCH has shifted from a growth story to a merger-arbitrage trade.
3. Ciena (CIEN) | Last Close ~$441.50 (+13.3%) | Optical Networking Re-Rates
Marvell’s Investor Day Hands Ciena a 13% Day
Ciena rose roughly 10% midday after Marvell raised its interconnect outlook and Evercore ISI pointed to the read-through.
| Metric | Value |
|---|---|
| Last Close | ~$441.50 (Yahoo Finance; other feeds show ~13.9%) |
| Previous Close | $389.69 (Monday, Oct 5) |
| Day’s Move | +13.3% (+$51.80) |
| Day’s Range | $392.00 – $442.55 |
| 52-Week Range | $147.36 – $637.51 |
| Market Cap | ~$62.6B |
| P/E / Dividend | ~98.6x (EPS $4.47) / None |
| Volume vs. Average | 4.81M vs. 2.28M (~2.1x) |
| Distance From High | About -31% |
| Analyst View | Buy (21 analysts); average target ~$513; Evercore Outperform, $550 |
| Support 1 / 2 / 3 | ~$420 / $392 / $389.69 |
| Resistance 1 / 2 / 3 | $442.55 / ~$513 / $550 |
Catalyst & Latest News: Marvell sees interconnects growing to about $65 billion at a 60–70% annual rate through 2030, above Ciena’s own roughly 30% growth framework. Jim Cramer also praised optical on Monday night.
Technicals: The stock opened at $393.58 and ran to the day’s high, which makes $392 the gap-support line.
Fundamentals: Last quarter’s revenue rose 37% to $1.67 billion with an $8.5 billion backlog, but two customers make up about 42% of sales.
Bull Case: AI optical bottleneck demand and targets near $550. Bear Case: A 98x trailing P/E, customer concentration and a 13% one-day run.
What to Watch:
- A hold above $420
- The $442.55 high
- Analyst target changes
Forecast: A close over $442.55 opens $513. A fill of the gap toward $392 is the risk case.
Why This Matters: CIEN is the optical-networking proxy for the AI build-out.
4. Marvell Technology (MRVL) | Last Close $287.01 (+5.81%) | $90 Billion Revenue Target
A $301 Intraday Spike and a $70–$90B Fiscal 2031 Revenue Ambition
Marvell closed at $287.01, touching its highest level since June at the intraday peak.
| Metric | Value |
|---|---|
| Last Close | $287.01 (after-hours $288.08) |
| Previous Close | $271.25 (Monday, Oct 5) |
| Day’s Move | +5.81% (+$15.76) |
| Day’s Range | $267.26 – $301.27 |
| 52-Week Range | $70.69 – $329.88 |
| Market Cap | Not confirmed |
| P/E / Dividend | ~40x forward (approx.) / Nominal |
| Volume vs. Average | 51.26M vs. ~22.1M (~2.3x) |
| YTD | Roughly +230–240% (derived from ~$85 start) |
| Analyst View | Strong Buy, 46 analysts; pre-event average target ~$291; Evercore Outperform, $433 |
| Support 1 / 2 / 3 | $271.25 / $267.26 / ~$250 |
| Resistance 1 / 2 / 3 | $301.27 / $316.43 / $329.88 |
Catalyst & Latest News: At its Investor Day, CNBC reports management projected fiscal 2028 revenue of $20 billion versus $18.17 billion expected, and fiscal 2031 revenue of $70–$90 billion versus a $47.04 billion consensus.
Technicals: The stock faded from $301 to a $287 close, a sign that sellers met the spike. Beta is 2.25.
Fundamentals: Management leans on custom AI silicon and interconnect growth, with the stock having more than tripled this year.
Bull Case: A far higher long-term revenue frame and target hikes (Evercore moved from $275 to $433). Bear Case: Valuation, a high beta and a stock now above the average target.
What to Watch:
- $271 as support
- A retest of $301
- More analyst target raises
Forecast: Above $301, the $316 June peak is next. Under $271, the gap closes.
Why This Matters: MRVL’s guide is the market’s latest vote on how big AI networking can get.
5. Vistra (VST) | Last Close ~$159–$160 (+~10%) | $4.2 Billion Federal Nuclear Loan
Washington Backs the Uprates, and Wall Street Pays Up
Vistra jumped after the Department of Energy confirmed a conditional loan of up to $4.2 billion for nuclear upgrades at plants in Pennsylvania and Ohio.
| Metric | Value |
|---|---|
| Last Close | Roughly $159–$160 (derived; feeds show +9.5% to +10.8%) |
| Previous Close | ~$144.92 (Monday, Oct 5; derived) |
| Day’s Move | Roughly +10% |
| Day’s Range | Not confirmed |
| 52-Week Range | Low not confirmed; high $217.10 |
| Market Cap | Roughly $50B+ (feeds vary) |
| P/E / Dividend | Not confirmed / Small |
| Volume vs. Average | Not confirmed |
| YTD | Not confirmed |
| Analyst View | Siebert Williams Shank Buy, $202 (Oct 2) |
| Support 1 / 2 / 3 | ~$150 / ~$144.92 / $140.02 |
| Resistance 1 / 2 / 3 | ~$165 / ~$180 / $202–$217.10 |
Catalyst & Latest News: The Motley Fool reports the loan would preserve nearly 4 GW and add about 433 MW of nuclear capacity, but it would also raise Vistra’s debt about 20% to roughly $24.7 billion. The loan is conditional.
Technicals: The stock gained about 3.5% Monday and roughly 10% Tuesday, a two-day run of about 14% off the $140.02 October 2 close.
Fundamentals: The uprates tie to power agreements, including Meta. TIKR notes a past-year margin near 9.3%.
Bull Case: Cheap federal financing, signed buyers and sector momentum from CEG. Bear Case: Conditional funding, higher leverage and a fast run-up.
What to Watch:
- A hold above $150
- Loan conditions and timing
- Peer moves in CEG and Talen
Forecast: Support at $150 keeps $165 reachable. Under $145 the move fades.
Why This Matters: VST shows the government is now a direct financier of nuclear expansion.
6. Lamb Weston (LW) | Last Price ~$48.30 (+8.4%) | Beat, Raise and a Euro Potato Problem
Fries Beat the Street: Adjusted EPS of $0.75 vs. $0.59
Lamb Weston reported fiscal first-quarter results before the open and raised its full-year outlook.
| Metric | Value |
|---|---|
| Last Price | ~$48.30 (as of 3:03 PM ET; final close not confirmed) |
| Previous Close | ~$44.57 (Monday, Oct 5; derived) |
| Day’s Move | +8.4% (intraday up to ~+11.7%) |
| Day’s Range | Not confirmed; traded near $49.80 at the high |
| 52-Week Range | $37.62 – $67.07 |
| Market Cap | Not confirmed |
| P/E / Dividend | Not confirmed / Regular dividend |
| Volume vs. Average | Not confirmed |
| 12-Month Trend | About -24% over one year |
| Analyst View | JPMorgan Neutral, $46; Stephens Equal Weight, $50 |
| Support 1 / 2 / 3 | $44.57 / $43.60 / ~$41–$42 |
| Resistance 1 / 2 / 3 | ~$50 / ~$55 / $67.07 |
Catalyst & Latest News: Net sales rose 1% to $1.67 billion, adjusted EBITDA fell 5.5% to $285.6 million, and net income was $29.1 million. Investing.com notes fiscal 2027 adjusted EPS guidance of $3.05–$3.35, up from $2.95–$3.25.
Technicals: The stock bounced from the low $40s on October 1–2 and ran into resistance just above $50.
Fundamentals: North America sales rose 5% on 7% volume growth, while International sales fell 8% and segment EBITDA dropped 54%.
Bull Case: A beat, a raise and seven straight quarters of North American volume growth. Bear Case: Weak European potato crop, a high debt load and a 55% drop in net income.
What to Watch:
- A close above $50
- International margin trends
- Analyst target changes
Forecast: A break over $50 opens $55. A loss of $44.57 returns the stock to the low $40s.
Why This Matters: LW is a value-turnaround test with a clear overhead ceiling.
7. Constellation Brands (STZ) | Earnings Beat, Stock Down After Hours | Call at 8 AM ET Wednesday
A $3.74 EPS Beat Meets a Guidance Midpoint Below Consensus
Constellation Brands beat estimates for a fourth straight quarter but shares fell after the guidance.
| Metric | Value |
|---|---|
| Last Close | Not confirmed ($112.99 on Oct 1) |
| After-Hours Move | -2.7% to -4.5% (feeds vary) |
| Previous Close | Not confirmed |
| 52-Week Low | $111.54 |
| Market Cap | ~$19.7B |
| P/E / Dividend | ~11x (EPS $10.50) / $1.03 per quarter (~3.6% yield) |
| Volume vs. Average | Average ~2.02M |
| Trend | Down about 17% over 12 months |
| Q2 Results | Adj. EPS $3.74 vs. ~$3.55–$3.61; revenue $2.63B vs. $2.54B |
| Support 1 / 2 / 3 | $111.54 / ~$105 / ~$100 |
| Resistance 1 / 2 / 3 | ~$113 / $122.48 / $130.62 |
Catalyst & Latest News: Beer net sales grew 5% to $2.47 billion on 5.5% shipment growth. Wine and Spirits sales rose 17% to $159.4 million. Beer operating margin fell 160 basis points to 39.0%.
Technicals: The stock was within about 1.3% of its 52-week low into the print, so any after-hours drop tests the low.
Fundamentals: Management held comparable fiscal 2027 EPS guidance at $11.20–$11.90, a $11.55 midpoint versus $11.72 consensus.
Bull Case: Four straight beats, 5.5% beer volume growth and a roughly 10x forward multiple. Bear Case: Guidance below consensus, margin pressure and continued softness at Modelo and Corona.
What to Watch:
- The 8:00 AM ET call
- Beer margin and depletion commentary
- Whether $111.54 holds
Forecast: If $111.54 breaks, round-number support sits near $105 and $100. A hold sets up a bounce toward $113.
Why This Matters: STZ is a classic “beat but guide light” setup, with a dividend yield near 3.6%.
8. Novavax (NVAX) | Last Close $11.32 (-9.87%) | Plague Fear Trade Unwinds
A 20% Monday Pop Gives Back Nearly 10% as the WHO Calls Risk “Low”
Novavax fell nearly 10% after the WHO said the risk of a plague epidemic was low, reversing part of Monday’s 20% gain.
| Metric | Value |
|---|---|
| Last Close | $11.32 (after-hours $11.36) |
| Previous Close | $12.56 (Monday, Oct 5, +20.08%) |
| Day’s Move | -9.87% (-$1.24) |
| Day’s Range | $10.88 – $13.33 |
| 52-Week Range | $6.20 – $13.39 |
| Market Cap | ~$1.87B |
| P/E / Dividend | N/A (EPS -$1.52) / None |
| Volume vs. Average | 19.37M vs. ~4.83M (~4x) |
| Short Interest | 31.8% of float, 10.3 days to cover |
| Analyst View | Buy (9 analysts); average target $14.00 |
| Support 1 / 2 / 3 | $10.88 / $10.28 / ~$9.28 |
| Resistance 1 / 2 / 3 | $12.56 / $13.39 / $14.00 |
Catalyst & Latest News: Fear tied to a suspected plague death at a Russian lab drove Monday’s squeeze. Moderna fell 7.75% on Tuesday. Finviz shows Novavax above its 20-, 50- and 200-day averages (roughly $10.36, $9.28 and $8.94, derived).
Technicals: RSI was about 58 on Finviz’s midday reading, with an ATR near $0.86, which means daily swings of 7–8% are normal.
Fundamentals: Trailing revenue was $413.8 million with a net loss of $247.7 million.
Bull Case: Elevated short interest, a Buy consensus and a hold above all major averages. Bear Case: Headline-driven spikes fade fast, and the fear trade has lost its trigger.
What to Watch:
- $10.88 (Tuesday’s low)
- Headlines on the Russian case
- Short-covering volume
Forecast: Holding $10.88 keeps a retest of $12.56 possible. Below $10.28, the next stop is near $9.28.
Why This Matters: NVAX is a short-squeeze case study where the news cycle sets the price.
9. Sable Offshore (SOC) | Last Close $3.47 (-1.14%) Monday; ~$3.57 Tuesday Intraday | Wall Street Piles In
Fresh Analyst Initiations and a Q4 Hondo Restart on the Calendar
Sable Offshore drew coverage from JPMorgan, William Blair and Stifel in recent weeks, and JPMorgan set a $10 target.
| Metric | Value |
|---|---|
| Last Close | $3.47 (Oct 5); Tuesday close not confirmed |
| Tuesday Intraday | ~$3.57 (+2.9%) |
| Previous Close | $3.51 (Friday, Oct 2, +6.69%) |
| Day’s Range (Oct 5) | $3.36 – $3.64 |
| 52-Week Range | $2.88 (June 30) – $20.74 (Oct 10, 2025) |
| Market Cap | ~$673M–$695M |
| P/E / Dividend | About -1.1x / None |
| Volume vs. Average | Oct 5: 6.70M; Oct 2: 10.47M |
| YTD | About -61.5% |
| Analyst View | 5 Buy, 1 Hold, 2 Sell; JPMorgan Overweight $10, Stifel Buy $8, Roth Buy $10 |
| Support 1 / 2 / 3 | ~$3.42 / $3.29 / $2.88 |
| Resistance 1 / 2 / 3 | $3.64 / ~$4.00 / ~$8.00 |
Catalyst & Latest News: Sable expects to restart Hondo in the fourth quarter and raise oil sales nominations. It operates the Santa Ynez Unit offshore California.
Technicals: SOC is hugging the low end of its range, well under its 200-day average, and its recent daily closes have stayed between roughly $3.29 and $3.51.
Fundamentals: The company is producing and selling oil but remains loss-making, with a consensus EPS estimate near -$1.72 for next year.
Bull Case: Consensus targets near $9.60 and a restart that adds barrels. Bear Case: Operating and regulatory hurdles, losses and two Sell ratings.
What to Watch:
- A close above $3.64
- Hondo restart timing
- Support at $3.29
Forecast: A break over $3.64 targets $4.00. Under $3.29, the $2.88 low is exposed.
Why This Matters: SOC is a deep-value recovery bet where analyst conviction is outrunning the price.
10. QTREX Quantum (QTEX) | Last Close ~$1.59 | Up Roughly 133% in a Week
A $1.54 Close, a 28% After-Hours Pop and a Deal “Within Weeks”
QTREX closed Monday at $1.54 after a 40% gain and ran as high as $1.97 after hours. This corrects the midday $1.29 figure that appeared in our October 5 penny stocks list.
| Metric | Value |
|---|---|
| Last Close | ~$1.59 (per StockAnalysis weekly board) |
| Previous Close | $1.54 (Monday, Oct 5) |
| Day’s Move | ~+3% |
| Day’s Range | Not confirmed (premarket high $1.77) |
| 52-Week Range | Not confirmed |
| Market Cap | ~$88.6M |
| P/E / Dividend | N/A (loss-making) / None |
| Volume vs. Average | ~71.3M (weekly board) |
| 1-Week Move | +133% |
| Analyst View | No Wall Street targets located |
| Support 1 / 2 / 3 | $1.54 / $1.10 / ~$0.90 |
| Resistance 1 / 2 / 3 | $1.77 / $1.97 / ~$2.50 |
Catalyst & Latest News: Independent tests showed isolation above 100 dB at 20 millikelvin. A binding commercial agreement with an unnamed quantum company is expected within weeks.
Technicals: The stock gapped from the $0.70–$0.90 range to above $1.50 in three sessions. A close under $1.54 would erase Monday’s gains.
Fundamentals: Cash was roughly $3.2 million at last report, which is thin for a company this size.
Bull Case: A signed deal could validate the technology. Bear Case: A missed timeline or an equity raise would hit a stock that has more than doubled in a week.
What to Watch:
- The deal announcement
- A hold above $1.54
- Offering or ATM language
Forecast: A confirmed deal could challenge $1.97. A fade under $1.54 targets $1.10.
Why This Matters: QTEX is the highest-risk name here, and a reminder that a one-week 133% run can reverse as fast.
Stocks to Watch Sector Snapshot: AI Infrastructure Leads, Small Caps Lag
AI infrastructure was the day’s theme: Ciena, Marvell, Nebius and Astera Labs rallied, and nuclear names (CEG, VST) surged on power contracts. Defensive and consumer names split, with Lamb Weston up on a beat and Constellation Brands slipping on guidance. The Russell 2000 fell 0.59%, so breadth was narrower than the records suggest. Sector forecast: Expect AI and power names to stay volatile after big one-day gains, and watch whether small caps catch up. For earlier consumer-side reads, see our stocks to watch on Aug 7, and for a biotech catalyst example, our Capricor Therapeutics forecast.
Stocks to Watch Tomorrow At a Glance
| # | Ticker | Last Close | Move | Catalyst | Key Support | Key Resistance | Bias |
|---|---|---|---|---|---|---|---|
| 1 | CEG | $300.40 | +12.25% | Google 20-yr nuclear deal | $287–$290 | $309.59 | Constructive above $290 |
| 2 | OPCH | $31.00 | +32.65% | $32.05 cash buyout | ~$30.50 | $32.05 | Merger arb |
| 3 | CIEN | ~$441.50 | +13.3% | Optical-networking re-rate | ~$420 | $442.55 | Extended |
| 4 | MRVL | $287.01 | +5.81% | $20B FY28 revenue outlook | $271.25 | $301.27 | Constructive |
| 5 | VST | ~$159–$160 | ~+10% | $4.2B DOE loan | ~$150 | ~$165 | Extended |
| 6 | LW | ~$48.30 | +8.4% | Beat and raise | $44.57 | ~$50 | Resistance test |
| 7 | STZ | n/c | AH -2.7% to -4.5% | Q2 beat, guide midpoint light | $111.54 | ~$113 | 52-week-low test |
| 8 | NVAX | $11.32 | -9.87% | WHO plague-risk comment | $10.88 | $12.56 | Fade risk |
| 9 | SOC | $3.47 (Oct 5) | ~+2.9% intraday | Analyst initiations, Hondo restart | $3.29 | $3.64 | Range-bound |
| 10 | QTEX | ~$1.59 | ~+3% | Quantum deal expected | $1.54 | $1.77 | Highest risk |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and small-cap, high-volatility stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
